Palbociclib (PD-0332991) HCl

Licensed by Pfizer Catalog No.S1116

Palbociclib (PD-0332991) HCl Chemical Structure

Molecular Weight(MW): 483.99

Palbociclib (PD-0332991) HCl is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays, respectively. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.

Size Price Stock Quantity  
USD 110 In stock
USD 170 In stock
USD 570 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

8 Customer Reviews

  • PD-0332991 causes inhibition of proliferation of EAC cells in a dose-dependent manner. Western blots showing the phosphorylation status of pRB at Ser780 and Ser795 after incubation with 125 nmol/L PD-0332991 for 24 and 72 hours. Reduction in cyclin A expression and the expression of RB2 (p130) tumor suppressor 72 hours after PD-0332991 treatment are shown (bottom). Total pRB (RB1) and actin are loading controls and T293 cell lysate (293) is a positive control for total pRB and phospho-pRB (Ph-RB). E, anchorage-independent growth of the 3 cell lines in the presence or absence (Cnt) of 125 nmol/L PD-0332991 for 3 weeks.

    Clin Cancer Res 2011 17(13), 4513-22. Palbociclib (PD-0332991) HCl purchased from Selleck.

    b, c MelJuso cells were treated for 12–48 h with 1 µM Selumetinib or 5 µM Palbociclib and the cells were fixed, stained with propidium iodide and cell cycle distribution was determined by flow cytometry (b) and whole cell extracts were fractionated by SDS-PAGE, transferred onto PVDF membrane and immuno-blotted with the indicated antibodies (c). Data is from a single experiment representative of three separate experiments with similar results. The data in (b) are mean ± S.D. from a single experiment with three replicate dishes of cell per data point; similar results were obtained in two additional experiments

    Cell Mol Life Sci, 2016, 73(4):883-900. Palbociclib (PD-0332991) HCl purchased from Selleck.

  • (A) Percentage of DN3a cells in S-phase (as gated on DAPI profile) from control (Zfp36l1/2fl/fl) and Zfp36l1/2fl/fl; CD2Cre (DCKO) mice, after 1 d of treatment with vector or palbociclib (drug).

    J Immunol, 2016, 197(7):2673-85. Palbociclib (PD-0332991) HCl purchased from Selleck.

     

    Patient tumor cell sensitivity to combinatorial treatment with histone deacetylase (HDAC)/cyclin-dependent kinase (CDK) inhibitors in 3-D culture. The effect of each drug or drug combination was assessed by fluorescent dye to identify live (green) and dead cells (red). Cells from breast reduction patients were used as non-cancer control in the assay.

    Pharmacogenomics J 2013 13(1), 94-104. Palbociclib (PD-0332991) HCl purchased from Selleck.

  •  

    Cdk4 is upregulated in ARMS and mMSCs transfected with PAX7-FKHR fusion gene (MP7F), and can be specifi cally inhibited. D: IF results showing overexpression of cdk4 in MP7F cells compared to parental mMSCs and reduced expression of cdk4 after treatment of MP7F cells with the cdk4 inhibitor, PD-0332991. E: IF results showing MyoD1 expression in parental mMSCs cells, and MP7F cells untreated and after treatment with the cdk4 inhibitor, PD-0332991.

    Clin Transl Oncol 2012 14(3), 197-206 . Palbociclib (PD-0332991) HCl purchased from Selleck.

    WM3734 melanoma cells were treated by PD-0332991 for 36 hours; melanoma cells treated by Doxorubicin (DXR)  at 0.5 μM is included as a control.

     

     

    Dr. Gao Zhang of University of Pennsylvania. Palbociclib (PD-0332991) HCl purchased from Selleck.

  • Serum-deprived T98G glioma cells are restimulated with serum(FBS) with or without 1 μΜ PD-0332991.

     

     

    Dr. Sabine Paternot and Dr Pierre Roger of IRIBHM, ULB, Brussels. Palbociclib (PD-0332991) HCl purchased from Selleck.

    P16INK4A knockdown in INK4A/ARF-wt human glioma cell LN319 potentiates PDGF-Apromoted anchorage-dependent growth in vitro. Soft agar growth of Ink4a/Arf-deficient mAst and LN444 cells treated with PD0332991. (A) IB analysis. (B) Quantification of soft agar assays. β-actin was used as a loading control in all IB experiments. Data are presented as mean ± s.d. and representative of two independent experiments. **, P < 0.01; ***, P < 0.001

    Dr. Kun-Wei Liu from University of Pittsburgh. Palbociclib (PD-0332991) HCl purchased from Selleck.

Purity & Quality Control

Choose Selective CDK Inhibitors

Biological Activity

Description Palbociclib (PD-0332991) HCl is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays, respectively. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.
Features Non-cytotoxic, and halts cancer cell growth & could be used in glioblastoma that has relapsed after temozolomide treatment (a chemotherapeutic used to treat many cancers).
Targets
CDK4/CyclinD3 [1]
(Cell-free assay)
CDK4/CyclinD1 [1]
(Cell-free assay)
CDK6/CyclinD2 [1]
(Cell-free assay)
9 nM 11 nM 15 nM
In vitro

PD 0332991 has little effect on other protein kinases including EGFR, FGFR, PGFR, IR. PD 0332991 is a non-ATP competitive inhibitor of Cdk4. PD 0332991 inhibits MDA-MB-435 breast carcinoma cells with IC50 of 66 nM, which is due to reduced Rb phosphorylation at Ser780. PD 0332991 inhibits thymidine incorporation into the DNA of Rb-positive human breast, colon, and lung carcinomas as well as human leukemias, with IC50 values ranging from 0.04-0.17 μM. PD 0332991 shows no activity in Rb-negative cells. PD 0332991 causes an accumulation of cells in G1 in MDA-MB-453 breast and Colo-205 carcinoma cells. [1] PD 0332991 also shows activity in 5T33MM myeloma cells (immunocompetent model) and sensitizes the cells to killing by bortezomib. [2] PD 0332991 inhibits luminal ER-positive as well as HER2-amplified breast cancer cell lines including MDA-MB-175, ZR-75-30, CAMA-1, MDA-MB-134, HCC-202 and UACC-893. PD 0332991 enhances the activity of tamoxifen and trastuzumab in these cell lines. PD 0332991 enhances the sensitivity of tamoxifen in the MCF7 tamoxifen-resistant cells. [3] A recent study shows that PD 0332991 could suppress malignant rhabdoid tumor (MRT) cell lines including MP-MRT-AN, KP-MRT-RY, G401, KP-MRT-NS and the sensitivity of the MRT cell lines to PD 0332991 is inversely correlated with expression of p16. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MOLM13 MW\LbY5ie2ViQYPzZZk> M4\ycVI1KGh? MljlTY5pcWKrdHnvckBw\iCFRFu0JIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[gVoIheGixc4Doc5J6dGG2aX;uJJdqfGhiSVO1NEBw\iByLkCwNkDPxE1? NYXwV4dROjR4NEGxNFM>
COLO205 NFvwZm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2jZXVczKGh? MYrBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5Nme3OnZDDhd{BqdmOxcoDvdoF1cW:wIH;mJHs{UF22aIntbYRqdmViaX70c{BFVkFid3n0bEBKSzVyIH;mJFAvODN4IN88US=> NHHZU|MzPDZ2MUGwNy=>
U937 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\hO|IhcA>? NH3wPVBCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3Onc4Pl[EBieyCrbnPvdpBwemG2aX;uJI9nKFt|SG30bJlucWSrbnWgbY51dyCGTlGge4l1cCCLQ{WwJI9nKDBwMUSg{txO MofVNlQ3PDFzMEO=
MOLM13 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnq4O|IhcA>? NXz1PVdZSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNU2xOOTNiY3XscJMhcGG{Yn;ybY5oKE[OVEOgTXRFKG23dHHueEBie3Onc4Pl[EBieyCrbnPvdpBwemG2aX;uJI9nKFt|SG30bJlucWSrbnWgbY51dyCGTlGge4l1cCCLQ{WwJI9nKDBwMEm2JO69VQ>? NX;we3JLOjR4NEGxNFM>
MOLM13 NX7WO3RKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3XucVczKGh? NIqwVFlCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JJNwemGoZX7pZk1z\XOrc4ThcpQhcHWvYX6gUW9NVTF|IHPlcIx{KGG|c3Xzd4VlKGG|IHnuZ49zeG:{YYTpc44hd2ZiW{PIYZRpgW2rZHnu[UBqdnSxIFTORUB4cXSqIFnDOVAhd2ZiMD6wPVYh|ryP Moj4NlQ3PDFzMEO=
MDA-MB-435 M{fEUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MojvNlQhcA>? MmTBTWM2OD1yLkG2JO69VQ>? NYfmSod2OTV6MEG4N|E>
K562 M4\XT2N6fG:2b4jpZ{BCe3OjeR?= M4XoVVk3KGh? NHrCPJpFVVOR NGe3Z3BKSzVyPUKg{txO MYmyOFQyPzV4Nh?=
DU145 MULDfZRwfG:6aXOgRZN{[Xl? MlnUPVYhcA>? NIr4codFVVOR NWToOlhRUUN3ME23MlUh|ryP M{TqR|I1PDF5NU[2
MDA-MB-231 NEjqbHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFj6VFkyKM7:TR?= MYOyOEBp NFnVPW5FVVOR MWPD[YxtKGO7Y3zlJIFzemW|dDDhd5Nme3OnZDDhd{Bi[2O3bYXsZZRqd25iYYSgS|EheGijc3W= MXeyOFQyPzV4Nh?=
MCF7 MlqwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYO1dY5YOSEQvF2= NEGyOFkzPCCq NX;pe3FoTE2VTx?= MXTD[YxtKGO7Y3zlJIFzemW|dDDhd5Nme3OnZDDhd{Bi[2O3bYXsZZRqd25iYYSgS|EheGijc3W= MWmyOFQyPzV4Nh?=
MCF7 MojXT4lv[XOnIFHzd4F6 M2PJWlUh|ryP MorQNlQhcA>? NUP4Z5N[TE2VTx?= M3jkZmlvcGmkaYTpc44hd2ZicnXjc41jcW6jboSgR2RMPC:leXPsbY5FOSCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKHKndHnuc4Jt[XO2b33hJJBpd3OyaH;yfYxifGmxbjDheEBU\XJ5OEC= MnTpNlQ1OTd3Nk[=
MDA-MB-231 M{OyW2tqdmG|ZTDBd5NigQ>? NFSwcI42KM7:TR?= MnvkNlQhcA>? NHH4UIhFVVOR NH7HUmZKdmirYnn0bY9vKG:oIILlZ49u[mmwYX70JGNFUzRxY4njcIlvTDFiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iC{ZYTpco9jdGG|dH;tZUBxcG:|cHjvdplt[XSrb36gZZQhW2W{N{iw NVu1N|BFOjR2MUe1OlY>
MDA-MB-231 MWjGeY5kfGmxbjDBd5NigQ>? MVmxMVExKM7:TR?= NHHo[2ozPCCq MlS2SG1UVw>? Mn\4[I9meyCwb4SgbY5lfWOnIHHwc5B1d3OrczDhd5Nme3OnZDDhd{BRSVKSIHPs[YF3[Wen MmPrNlQ1OTd3Nk[=
MCF7 MlTLSpVv[3Srb36gRZN{[Xl? NVT4OVBUOS1zMDFOwG0> NVO3dpJ3OjRiaB?= M4Xpc2ROW09? M1z1R4Rw\XNibn;0JIlv\HWlZTDhdI9xfG:|aYOgZZN{\XO|ZXSgZZMhWEGUUDDjcIVifmGpZR?= NW\pUINlOjR2MUe1OlY>
MDA-MB-231 M{jBSGZ2dmO2aX;uJGF{e2G7 NXXvcppvOC53LUGg{txO MYe0PEBp M3TQNmROW09? MVXoZZMhdm9iQ3XscEBkgWOuZTDhdpJme3RiYYPz[ZN{\WRiYYOgZYNkfW23bHH0bY9vKGG2IIP1Zk1IOSCyaHHz[S=> MUSyOFQyPzV4Nh?=
MCF7 NYSxfmV1TnWwY4Tpc44hSXO|YYm= M33t[|AvPS1zIN88US=> NWDXWFQ3PDhiaB?= NFj5cXhFVVOR NX3I[VdjcGG|IH7vJGNmdGxiY4njcIUh[XK{ZYP0JIF{e2W|c3XkJIF{KGGlY4XteYxifGmxbjDheEB{fWJvR{GgdIhie2V? NX7RPHFvOjR2MUe1OlY>
697 M{LLSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MonGTWM2OD1zNEiuN|ghdk1? NYPlSGk1W0GQR1XS
P12-ICHIKAWA M331PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn3oTWM2OD17Nj6wOEBvVQ>? MVzTRW5ITVJ?
NB69 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4PLN2lEPTB;MU[xMlghdk1? MlTnV2FPT0WU
EoL-1 NIXJ[JFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\2c|ZvUUN3ME2xPFcvOjZibl2= M2X3NXNCVkeHUh?=
BHT-101 MmXzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjQfY5KSzVyPUG5PE4zPSCwTR?= NYfNZYp6W0GQR1XS
SK-NEP-1 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHTZeJBKSzVyPUKyNE4xOiCwTR?= MmLSV2FPT0WU
MHH-NB-11 M1jjOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3PKNGlEPTB;MkKwMlE6KG6P M4n2XHNCVkeHUh?=
AsPC-1 NVTB[oU{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTJ3Mj61N{BvVQ>? M4LaWXNCVkeHUh?=
ES1 NFjxbIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTJ3Nj6yOUBvVQ>? MoTpV2FPT0WU
LAMA-84 MonsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jPRWlEPTB;MkW4MlE6KG6P NFzvO4VUSU6JRWK=
MOLT-16 M3zyUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXxO4p7UUN3ME2yOVgvPDlibl2= NGnDSWxUSU6JRWK=
ES7 NHPiUWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{O1UWlEPTB;MkezMlA6KG6P MVXTRW5ITVJ?
KY821 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTNzND6xJI5O NHX1VIhUSU6JRWK=
RT-112 NITYNY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV7JR|UxRTN{MT6wOUBvVQ>? NILBWmVUSU6JRWK=
HL-60 NHnVdYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTN2MD62OkBvVQ>? MUTTRW5ITVJ?
MOLT-4 Mk\IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoTZTWM2OD1|NEWuNVMhdk1? MofLV2FPT0WU
KARPAS-45 M1zkfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTN5Nj6xOkBvVQ>? NY[3eFZIW0GQR1XS
SK-N-AS MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2PEPGlEPTB;M{i3Mlg{KG6P NInYPWxUSU6JRWK=
CTB-1 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFfnXYpKSzVyPUSwOU4xOiCwTR?= NIfZSo1USU6JRWK=
NKM-1 MkP6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWPNbnp1UUN3ME20NVEvQDlibl2= M17IXHNCVkeHUh?=
HTC-C3 NUXZcnBXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\2TYJDUUN3ME20N|IvQTVibl2= NFTZdmxUSU6JRWK=
BE-13 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3rsZmlEPTB;NES0MlI4KG6P M2jiNXNCVkeHUh?=
KOSC-2 NYPPSFl4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTR4Nj65JI5O MXHTRW5ITVJ?
NB14 NFzmXI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGK3[ZZKSzVyPUS4N{42QCCwTR?= NF2xbGlUSU6JRWK=
CAL-27 NYPie2tvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\xTWM2OD12OUSuOVkhdk1? NH\hUGtUSU6JRWK=
H9 M2\uZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn7nTWM2OD12OUWuOFMhdk1? Ml;FV2FPT0WU
RS4-11 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\3TWM2OD13MESuO|Mhdk1? M{fxe3NCVkeHUh?=
PA-1 M37XV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MorQTWM2OD13MEmuPFYhdk1? NILw[nhUSU6JRWK=
MV-4-11 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFrGNmVKSzVyPUWxN{45PSCwTR?= MmDGV2FPT0WU
OS-RC-2 NGD5T4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4P1fWlEPTB;NUKxMlYzKG6P NWT1PWtlW0GQR1XS
RPMI-8226 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3L2N2lEPTB;NUK2Mlg3KG6P NVjVN3BUW0GQR1XS
HGC-27 MoHVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVnJR|UxRTV4ND65PUBvVQ>? MYfTRW5ITVJ?
CHP-212 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVznWJhNUUN3ME21PVMvPTlibl2= NVHpWm1IW0GQR1XS
NB10 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUDTeoZMUUN3ME21PVkvOThibl2= NGH4PIxUSU6JRWK=
HH NFzyS4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{HHRmlEPTB;NUm5MlQ{KG6P NV2yOpo5W0GQR1XS
EW-16 M4DncWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTZyMz61NkBvVQ>? NXj1eGlwW0GQR1XS
ES8 NVH5XodoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37kZ2lEPTB;NkC1MlIyKG6P NVLhWFlLW0GQR1XS
HAL-01 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fCdGlEPTB;NkC1MlY4KG6P NXj2VYNKW0GQR1XS
A204 NF;2fXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2fJXWlEPTB;NkOzMlkyKG6P MWPTRW5ITVJ?
MHH-PREB-1 MmDDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTZ|Nj65PUBvVQ>? NX\uT2pvW0GQR1XS
EM-2 NIrydGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV7JR|UxRTZ3MD62OEBvVQ>? NF;CV3JUSU6JRWK=
BV-173 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF7tblhKSzVyPU[1Nk41QCCwTR?= MVPTRW5ITVJ?
ONS-76 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTZ5Nz64NkBvVQ>? M17pb3NCVkeHUh?=
KM-H2 NGP3c2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIOyVFRKSzVyPU[5OU42PCCwTR?= NFfQXopUSU6JRWK=
D-263MG MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWfKb3l1UUN3ME23NVcvOTJibl2= MVTTRW5ITVJ?
ES3 NWj2cXR2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX7BeG45UUN3ME23NlgvQTNibl2= NGD1d3pUSU6JRWK=
VA-ES-BJ NX3HXmZbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV3XSXpsUUN3ME23N|IvOjdibl2= NUPPTI8yW0GQR1XS
NBsusSR NF;TUYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWDrd|hbUUN3ME23OFIvQTlibl2= MVLTRW5ITVJ?
NCI-H520 NYL5bJZyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUf0RWtTUUN3ME23OFYvPTJibl2= Mn3GV2FPT0WU
ES5 NVXHUG8xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlnpTWM2OD15NUKuPEBvVQ>? MlXLV2FPT0WU
T-24 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIr3OmpKSzVyPUe3PE44OSCwTR?= MmrQV2FPT0WU
SW962 MoOyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;QTWM2OD16MEiuOlMhdk1? NIrBNoVUSU6JRWK=
EW-3 MlvtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3fTXmlEPTB;OEC4Mlc3KG6P NVzSdYhVW0GQR1XS
RXF393 NUe0eno6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\WSoFCUUN3ME24NVIvPzlibl2= NVyzZpNRW0GQR1XS
U251 NUXrU2V6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2nuZ2lEPTB;OEGzMlg5KG6P MlrGV2FPT0WU
CAMA-1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnjiTWM2OD16M{OuPVQhdk1? NV74cZNGW0GQR1XS
JVM-3 NVPJbJdOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4PaWWlEPTB;OEWxMlc5KG6P NWn2W5FmW0GQR1XS
COLO-800 NYDVeZNIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVfJR|UxRTh7Nz63PEBvVQ>? NHW3dpVUSU6JRWK=
OVCAR-5 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFLxd2xKSzVyPUmwNE4yKG6P NGH2eY5USU6JRWK=
LB1047-RCC MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI\6codKSzVyPUmyO{42PiCwTR?= M1;rUXNCVkeHUh?=
SW954 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG[5WZhKSzVyPUmyPU41OSCwTR?= M{nBcHNCVkeHUh?=
J-RT3-T3-5 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlniTWM2OD17M{[uNFYhdk1? NYHQW3ZOW0GQR1XS
Mewo MkThS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;2TWM2OD17M{[uOkBvVQ>? M4\nZnNCVkeHUh?=
NCI-H1770 NUPKWHJXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFfVOlVKSzVyPUm0NE42PSCwTR?= NUDXSohIW0GQR1XS
HO-1-N-1 NIjBfmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHTSc2JKSzVyPUm2Nk45OSCwTR?= MYfTRW5ITVJ?
HSC-3 M3vqSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1vXNmlEPTB;OU[2MlQ5KG6P MWjTRW5ITVJ?
TYK-nu NYC1c2NnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MonYTWM2OD17OUiuNlUhdk1? MVrTRW5ITVJ?
KYSE-150 MlLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXfVfm96UUN3ME2xMlAxODd4IN88US=> MUXTRW5ITVJ?
SN12C MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTFwMEC4O|Uh|ryP NXjYdoVNW0GQR1XS
MOLT-13 NHPaPVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGrlOFNKSzVyPUGuNFE1OjFizszN NGPz[lhUSU6JRWK=
TE-11 MojKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTFwMES4NVIh|ryP NITGZ21USU6JRWK=
DB MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGD4S|VKSzVyPUGuNFczPzNizszN M2qxWXNCVkeHUh?=
CAL-39 MkXuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3fLeGlEPTB;MT6wO|UzOiEQvF2= MnPNV2FPT0WU
A3-KAW MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTFwMEi0NFgh|ryP NVLwSWxTW0GQR1XS
CHP-134 M4TI[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnvrTWM2OD1zLkGxPFA4KM7:TR?= MVPTRW5ITVJ?
TGW MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3izXWlEPTB;MT6xNlM6PSEQvF2= M3u0PHNCVkeHUh?=
QIMR-WIL M3rD[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWLObolxUUN3ME2xMlE{OTN2IN88US=> NW\a[5liW0GQR1XS
NCI-SNU-1 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTFwMU[zOVQh|ryP NVfM[mlJW0GQR1XS
CGTH-W-1 M3vwbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVL5T3lrUUN3ME2xMlE4OTh4IN88US=> MomzV2FPT0WU
MHH-ES-1 Mk\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\CdIk2UUN3ME2xMlE4QTh4IN88US=> NFfPeY5USU6JRWK=
LB2241-RCC NHv0PIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTFwMUi2NkDPxE1? Mn:0V2FPT0WU
ML-2 NHO4OFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NELWdWNKSzVyPUGuNlA4OzRizszN NGXXXpRUSU6JRWK=
COR-L23 NGDGZWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVzSdWN5UUN3ME2xMlIzQTN|IN88US=> NFzrbWtUSU6JRWK=
BFTC-905 MonPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3;jSmlEPTB;MT6yOFI3PyEQvF2= NI\yfFJUSU6JRWK=
Hs-578-T NGnHO5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHmzUXFKSzVyPUGuNlU5OTdizszN NH\UcFBUSU6JRWK=
KG-1 NWfFfWNNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEPrd3NKSzVyPUGuNlY3QDZizszN M1PWbnNCVkeHUh?=
HEL NUXv[3E1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVLhPIE{UUN3ME2xMlI6OzN6IN88US=> NEXiNYdUSU6JRWK=
A549 NVHtfWR[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2D1RmlEPTB;MT6yPVM6QSEQvF2= MlLZV2FPT0WU
COLO-741 MorCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3nWe2lEPTB;MT6zNlA5QSEQvF2= M33qUHNCVkeHUh?=
PC-3 NVjaRpRLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlL4TWM2OD1zLkO1NlIyKM7:TR?= MX3TRW5ITVJ?
HOS MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13vN2lEPTB;MT6zOVI6PiEQvF2= MVXTRW5ITVJ?
HT-1080 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3T6TWlEPTB;MT6zO|UyQSEQvF2= MlLUV2FPT0WU
TE-8 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13oNWlEPTB;MT60NVc4PCEQvF2= M4\nRnNCVkeHUh?=
BHY M1vjTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\YepFKSzVyPUGuOFY6OjNizszN Mm\sV2FPT0WU
BB65-RCC MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7iUoZKSzVyPUGuOVA2OjhizszN NV\tOnpnW0GQR1XS
HN M2fLdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHTpPZVKSzVyPUGuOVQxPzFizszN M3XFW3NCVkeHUh?=
NCI-H441 NXy0S2hnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{DxSmlEPTB;MT61OFkxPyEQvF2= MU\TRW5ITVJ?
RPMI-8866 NFHvVIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX7RdIJoUUN3ME2xMlU5PTB5IN88US=> MW\TRW5ITVJ?
CAL-62 NFLTd3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlzCTWM2OD1zLk[wPFYzKM7:TR?= MWrTRW5ITVJ?
MG-63 NGmyPGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml7lTWM2OD1zLk[xPFE{KM7:TR?= M1LKZ3NCVkeHUh?=
SK-LU-1 NWPaeZNxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTFwNkKxOVIh|ryP M1HlRXNCVkeHUh?=
BCPAP NV7wSXlRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTFwNk[0OVch|ryP MWfTRW5ITVJ?
22RV1 NFvoN4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\odWlEPTB;MT62O|g1OyEQvF2= MojKV2FPT0WU
T47D NV3Vc4FwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3f2fGlEPTB;MT62PFA3OSEQvF2= NHXqO|FUSU6JRWK=
MSTO-211H MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2HpR2lEPTB;MT62PVYxOyEQvF2= MVfTRW5ITVJ?
DEL NGfXUoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEHoNXZKSzVyPUGuO|AzPzNizszN NFL0OJNUSU6JRWK=
H4 MkmyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;iZ4JKSzVyPUGuO|MzOTJizszN NETIbJVUSU6JRWK=
CAL-51 M3rieWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWH5eWRLUUN3ME2xMlc1QDV3IN88US=> M3TyOnNCVkeHUh?=
ABC-1 Mnn1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPJcGxKSzVyPUGuO|g2QDJizszN MlvSV2FPT0WU
MZ2-MEL MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVzjbGpoUUN3ME2xMlc6PTR{IN88US=> NFrqXHhUSU6JRWK=
YKG-1 MkOzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjTbWpKSzVyPUGuPFExPjFizszN MnfpV2FPT0WU
KM12 M3HOS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEfYU41KSzVyPUGuPFE3ODJizszN Mn3oV2FPT0WU
L-363 MnzRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFHwO3JKSzVyPUGuPFc1OTJizszN MmDwV2FPT0WU
KU812 NUH2cXV1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NID4WHNKSzVyPUGuPFkzQDJizszN MVLTRW5ITVJ?
LOXIMVI M4XGVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWLRe2c3UUN3ME2xMlkyOjJ6IN88US=> MYrTRW5ITVJ?
G-401 M4X5Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTFwOUK0Nlgh|ryP NGXPe5pUSU6JRWK=
SW780 M37rSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH7acmZKSzVyPUGuPVYzPDZizszN NGHrOmpUSU6JRWK=
SW872 Mkf1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTFwOUizN{DPxE1? NGD3OlBUSU6JRWK=
NB7 Mny4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmjMTWM2OD1zLkm5N|I{KM7:TR?= M162UnNCVkeHUh?=
T98G MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTJwMEC2OlYh|ryP NVT4cXpQW0GQR1XS
SW1710 NYDBS5VtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn[4TWM2OD1{LkC2PVQ2KM7:TR?= NUHwdYdSW0GQR1XS
NCI-H1573 Moe3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTJwMEeyPVgh|ryP M1vmT3NCVkeHUh?=
KE-37 NXPT[HlsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDLeGhMUUN3ME2yMlA5QTVzIN88US=> M3fOXHNCVkeHUh?=
786-0 NUC4RphJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTJwMUW0N|kh|ryP NGLhfHZUSU6JRWK=
SAS MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmW5TWM2OD1{LkKwN|c1KM7:TR?= NGXLUVhUSU6JRWK=
CAL-54 NV3sdnB6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4DhO2lEPTB;Mj6yNFQyOyEQvF2= NX;POYREW0GQR1XS
SF268 M3jkOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTJwMkOxNlIh|ryP MWDTRW5ITVJ?
SW620 MlPHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NELmbHpKSzVyPUKuNlYyPjlizszN NYHwZ|JIW0GQR1XS
MN-60 Moe0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXPKZlJmUUN3ME2yMlMyODZizszN NWfteJlNW0GQR1XS
EFO-27 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHP5e2NKSzVyPUKuN|IxPThizszN NHLheYpUSU6JRWK=
NCI-H747 NILoU2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXj2XoV3UUN3ME2yMlMzOTl7IN88US=> M1LjdXNCVkeHUh?=
HCC2218 MmjWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnPFTWM2OD1{LkO1N|c1KM7:TR?= NVTKeZI6W0GQR1XS
MIA-PaCa-2 M2D5fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXLTWM2OD1{LkO2OFM4KM7:TR?= NH;pfYpUSU6JRWK=
SJSA-1 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFftcmdKSzVyPUKuN|c4QTZizszN MkTGV2FPT0WU
RKO NWLqPYl6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3vUVWlEPTB;Mj6zPFQ6PiEQvF2= MXTTRW5ITVJ?
NB6 NX2wd|dxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmnuTWM2OD1{LkSwN|c1KM7:TR?= M2LwUXNCVkeHUh?=
ES4 Mnv2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTJwNEW0NlIh|ryP MlLzV2FPT0WU
EGI-1 M13L[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3j2TGlEPTB;Mj60Olg5OyEQvF2= NFXoWoZUSU6JRWK=
CTV-1 NFXGOnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTJwNUK3O|Mh|ryP Ml3IV2FPT0WU
NCI-H1355 NWLBRXJ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1[2WGlEPTB;Mj61OVk2OSEQvF2= NFvOd|JUSU6JRWK=
GT3TKB M1qxcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGCyRVlKSzVyPUKuOVkyQTlizszN Mnr5V2FPT0WU
SK-HEP-1 M3HjS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHv3S2xKSzVyPUKuOVkzPjZizszN MlnRV2FPT0WU
GAMG NXXKTnVUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTJwNUmzPVQh|ryP MWXTRW5ITVJ?
SK-MES-1 NGHkTJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3K0SmlEPTB;Mj62NVgxOyEQvF2= MVXTRW5ITVJ?
RO82-W-1 MkfQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1PtfmlEPTB;Mj62NlA2PyEQvF2= M3zQXHNCVkeHUh?=
ECC10 M{PKVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUG3fWtzUUN3ME2yMlcxOjB4IN88US=> NHXjTXdUSU6JRWK=
MCF7 NX3kRolxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTJwN{G0OlQh|ryP MkXwV2FPT0WU
D-283MED NWLSWG1vT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGTMO4VKSzVyPUKuO|I1OyEQvF2= MkfkV2FPT0WU
RPMI-7951 NULvXoFIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{C2N2lEPTB;Mj63OVY6PCEQvF2= M2XzRnNCVkeHUh?=
Ramos-2G6-4C10 NFPudFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonWTWM2OD1{Lke3NFk6KM7:TR?= M13PUnNCVkeHUh?=
KGN NYm2OFZXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF[xZmRKSzVyPUKuPFE5QDRizszN NVTwRZlNW0GQR1XS
NUGC-3 NV;PWmZpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\uTWM2OD1{LkiyOVA2KM7:TR?= M3vtRXNCVkeHUh?=
NCI-H292 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWSzWplmUUN3ME2yMlg2ODV|IN88US=> NUjZOW93W0GQR1XS
Becker NV;ReZYxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\oU2hoUUN3ME2yMlk2QDN{IN88US=> MkO0V2FPT0WU
NCI-H1299 NYfpNVlDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3fnNGlEPTB;Mz6wOVI3OyEQvF2= MlnJV2FPT0WU
ETK-1 NUPjWmxFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYfJR|UxRTNwMEW0N{DPxE1? NHjJOW5USU6JRWK=
TK10 MnjtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3HdVQxUUN3ME2zMlIxOTZ3IN88US=> NHnOboxUSU6JRWK=
VMRC-RCZ MlPKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1v5d2lEPTB;Mz6zOlQ5QCEQvF2= MoS1V2FPT0WU
YH-13 NIPUPVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml7FTWM2OD1|LkS0NFc6KM7:TR?= MV\TRW5ITVJ?
DU-145 NFS2OGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTNwNE[yOlkh|ryP MV;TRW5ITVJ?
SW1088 NHX6NXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVy2TJRzUUN3ME2zMlQ4PDdizszN NISwN2JUSU6JRWK=
HOP-92 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUX4cnd6UUN3ME2zMlUxOzR{IN88US=> NGi1d3hUSU6JRWK=
KP-N-YS MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4rWR2lEPTB;Mz62NlE{QSEQvF2= NH;5d4lUSU6JRWK=
NCI-H460 NEDBV2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUPDeFJHUUN3ME2zMlY3PzNizszN MoDKV2FPT0WU
U-2-OS MoexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXKTWM2OD1|LkeyOVM2KM7:TR?= MXvTRW5ITVJ?
A101D MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTNwN{[5N|Yh|ryP M4rjbXNCVkeHUh?=
MDA-MB-231 M{HuZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEXJWlBKSzVyPUOuPFE6PTFizszN NHzpWlVUSU6JRWK=
IST-MES1 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4LDemlEPTB;Mz64N|Ih|ryP MnX2V2FPT0WU
COR-L105 M3\KSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\uR5NKSzVyPUSuNFE5KM7:TR?= MVjTRW5ITVJ?
NCI-H1437 NXr1UY8yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1G2ZmlEPTB;ND6wNlMxOiEQvF2= MmS5V2FPT0WU
CAL-85-1 NYjZ[YJPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVvNSY9JUUN3ME20MlAzPDZzIN88US=> MXrTRW5ITVJ?
MZ1-PC NIX6fnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4TTd2lEPTB;ND6xPFU2PiEQvF2= MVjTRW5ITVJ?
VM-CUB-1 NYTj[I5iT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NED6OFZKSzVyPUSuN|EzQDRizszN NWnodIN7W0GQR1XS
CHL-1 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{jL[WlEPTB;ND6zNlE3QSEQvF2= M2jPUXNCVkeHUh?=
MDA-MB-361 NVfZOXFRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoK2TWM2OD12LkOzNVU{KM7:TR?= MWHTRW5ITVJ?
NCI-H661 Mm[wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\vSXRKSzVyPUSuOVAxQTJizszN NGq0do9USU6JRWK=
EW-11 M2nXT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHzKNmxKSzVyPUSuOVIzOzFizszN NFy0dGhUSU6JRWK=
BEN NEfPO3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXv2PJJUUUN3ME20MlUzQDF3IN88US=> NYfHOIdmW0GQR1XS
BFTC-909 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkSwTWM2OD12LkW2Nlc2KM7:TR?= MkXPV2FPT0WU
NCI-H2087 M{HjO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVTBOlI6UUN3ME20MlU5OTZ2IN88US=> MVLTRW5ITVJ?
RVH-421 NGnncWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1G0SmlEPTB;ND62OlY6KM7:TR?= NWfnUYtQW0GQR1XS
P30-OHK MmSxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkO2TWM2OD12Lk[4NFA5KM7:TR?= NEDJTYFUSU6JRWK=
NCI-H28 NY\OU4Q3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFO0Z|VKSzVyPUSuPFE3PjFizszN M1LSdnNCVkeHUh?=
ES6 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHXZTHlKSzVyPUSuPFMxOTZizszN NXHuT4lEW0GQR1XS
769-P MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTRwOEW5NlYh|ryP MXTTRW5ITVJ?
OE33 NV7GcmZqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF:1XodKSzVyPUSuPFgyPjFizszN Ml\wV2FPT0WU
SW982 NHPLNIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTRwOUWwOlEh|ryP MlLEV2FPT0WU
A388 M3fMcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTVwMEK5PFMh|ryP M2fDcHNCVkeHUh?=
TI-73 NGL3e49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnG5TWM2OD13LkC2NVk1KM7:TR?= M3TRSHNCVkeHUh?=
HCT-116 MmC5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\H[2lEPTB;NT6wPVg5QSEQvF2= MXLTRW5ITVJ?
HuP-T3 M1zXOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTVwMUi3NFkh|ryP NH;U[WRUSU6JRWK=
G-402 MmrpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1X0XmlEPTB;NT6xPVQyPiEQvF2= NXHkfZgyW0GQR1XS
NCI-H1792 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYHnPIJ{UUN3ME21MlI1PjJ{IN88US=> NVzRcXRHW0GQR1XS
NCI-H209 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml\vTWM2OD13LkK1PVQzKM7:TR?= MUXTRW5ITVJ?
NCI-H1650 NWDIVVY1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYn0SINPUUN3ME21MlMxPjN2IN88US=> M2jLNXNCVkeHUh?=
LCLC-97TM1 M3njXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnTCTWM2OD13LkOxPFA5KM7:TR?= NYDZ[lhlW0GQR1XS
S-117 NUjMeG5vT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4HxV2lEPTB;NT6zOlk4PiEQvF2= MX\TRW5ITVJ?
GI-ME-N M{fLWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTVwM{m2PFEh|ryP NITtTFlUSU6JRWK=
NCI-H2122 NIX2OWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4D1cWlEPTB;NT60PVM6PyEQvF2= MlTBV2FPT0WU
NCI-H1793 M2LJb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\hNmlEPTB;NT62O|U6OyEQvF2= MWTTRW5ITVJ?
C2BBe1 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnBc5NZUUN3ME21MlcxODh6IN88US=> MYnTRW5ITVJ?
TE-12 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2W3V2lEPTB;NT64NFU2PiEQvF2= MmTXV2FPT0WU
LCLC-103H NVvKdoRXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHnzT5lKSzVyPUWuPVE4KM7:TR?= MkO5V2FPT0WU
A673 NFPBZmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3rWWGlEPTB;NT65NVk{OiEQvF2= NUOzfnNmW0GQR1XS
BB30-HNC MmXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3jxNWlEPTB;NT65PFM3KM7:TR?= NYrVZW5RW0GQR1XS
SF295 NV;WR4xKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTZwMEC0NlIh|ryP NIXvNHpUSU6JRWK=
KU-19-19 NX\3NGg6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\HZYI5UUN3ME22MlAyPzNzIN88US=> NIK1SGxUSU6JRWK=
CFPAC-1 NV33Oo1vT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWruRoVLUUN3ME22MlA1PDR|IN88US=> MnnSV2FPT0WU
LoVo NF31UHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\BdIdZUUN3ME22MlA2ODZ|IN88US=> NILPR2VUSU6JRWK=
8505C NXX2b3RIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTZwMEe1O|Mh|ryP MWPTRW5ITVJ?
GMS-10 M37OXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXfsOJo2UUN3ME22MlE2ODB{IN88US=> NGnzbYpUSU6JRWK=
Ca9-22 MmTtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVm2WXNqUUN3ME22MlE3PzFizszN M3LOS3NCVkeHUh?=
DOK Ml7nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1u4O2lEPTB;Nj6yNlA4OiEQvF2= NXX3bplJW0GQR1XS
FADU NFHkXIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoXaTWM2OD14LkK2NFM6KM7:TR?= MmnhV2FPT0WU
BxPC-3 NVnPUHJ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;uWG5KSzVyPU[uNlc{OiEQvF2= MV\TRW5ITVJ?
CAL-33 NYD6WYxiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIGxNYpKSzVyPU[uNlkzODFizszN NWXIRYJ2W0GQR1XS
SHP-77 NV;GfYR5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIHXfFVKSzVyPU[uN|E2OTJizszN NXixNIZKW0GQR1XS
LXF-289 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3vjfGlEPTB;Nj6zN|Q2PSEQvF2= Ml3qV2FPT0WU
GB-1 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3ex[GlEPTB;Nj6zPFIh|ryP MYPTRW5ITVJ?
KS-1 MlrKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIm3Z4RKSzVyPU[uN|g1PDdizszN M2eyNXNCVkeHUh?=
D-502MG MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTZwNEKzO|Yh|ryP NEHrSFdUSU6JRWK=
LAN-6 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2rX[WlEPTB;Nj61NVAzOyEQvF2= NIjrVIlUSU6JRWK=
H-EMC-SS MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHLveFBKSzVyPU[uOVYyPDdizszN M3jJdnNCVkeHUh?=
LC-2-ad NVnHcIxbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2jXWGlEPTB;Nj62NFA4PiEQvF2= MVfTRW5ITVJ?
NCI-H1693 NHTZNmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmD2TWM2OD14Lk[yNlE2KM7:TR?= MWfTRW5ITVJ?
SK-N-FI MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEfwcmRKSzVyPU[uO|UxPDRizszN NGXQR4RUSU6JRWK=
D-423MG NViwdpByT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTZwN{[xNVch|ryP MUTTRW5ITVJ?
KNS-42 Mo\ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{TuWWlEPTB;Nj63PFE6PyEQvF2= NI\kTIZUSU6JRWK=
GCT M3;Ebmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn3pTWM2OD14LkmzPEDPxE1? NGrL[INUSU6JRWK=
DSH1 M3jsRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3vRU2lEPTB;Nz6wOlM{KM7:TR?= NWfxeYE4W0GQR1XS
D-247MG MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmDsTWM2OD15LkC3PFgyKM7:TR?= MkjEV2FPT0WU
NCI-SNU-5 Ml\ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTdwMUizO|Eh|ryP NInFTllUSU6JRWK=
TE-6 NIfFcpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\UTWM2OD15LkKwOlAyKM7:TR?= NVTBUYduW0GQR1XS
NOMO-1 NITxRodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVjMUFdPUUN3ME23MlIzOTJ5IN88US=> MYnTRW5ITVJ?
NB17 Mo\zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIO0XVJKSzVyPUeuN|A{ODlizszN NFT1VIpUSU6JRWK=
EW-22 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTdwM{SzOFgh|ryP M{fY[HNCVkeHUh?=
EW-13 M1[3VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\oPIZKSzVyPUeuN|UyPjJizszN NXWxcI9NW0GQR1XS
DOHH-2 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlfVTWM2OD15LkS0NFIh|ryP NFX6ZXJUSU6JRWK=
TGBC1TKB M{O0R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHx[IdKSzVyPUeuOFk5QTlizszN NWOwfWVvW0GQR1XS
GR-ST MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTdwNUK1PVQh|ryP NUfpWGZ5W0GQR1XS
KYSE-520 NYSwRlBDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoTBTWM2OD15LkW1OVE2KM7:TR?= M2rBSnNCVkeHUh?=
CAPAN-1 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEX6WJVKSzVyPUeuOVk2OSEQvF2= NXSyUYw1W0GQR1XS
HCE-4 Mn:zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTdwNkKyO|kh|ryP NX[5SpJHW0GQR1XS
MLMA M2LmXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;EdW1jUUN3ME23MlYzQTV5IN88US=> NGrpVJFUSU6JRWK=
HT-144 M{XtR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXz4W4p6UUN3ME23MlY2OzZ6IN88US=> NXm5XpI6W0GQR1XS
KYSE-180 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HoRmlEPTB;Nz63NVE3QSEQvF2= M1;jTnNCVkeHUh?=
TE-5 NVnL[pBnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV7JR|UxRTdwOUW5O|Eh|ryP MnfnV2FPT0WU
IGROV-1 M{fsR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkSxTWM2OD15Lkm4OVUyKM7:TR?= NUDMV4ZCW0GQR1XS
NCI-H1581 NWDNNlRoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHL5bo9KSzVyPUiuNFEzKM7:TR?= NEXLTmNUSU6JRWK=
SW1990 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGWzclNKSzVyPUiuNFQ3PTlizszN NXnLd|lmW0GQR1XS
EFM-19 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;YTWM2OD16LkC4OVQ2KM7:TR?= MWPTRW5ITVJ?
OGR-1 NX7mZ4pMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRThwNEOwNlMh|ryP MY\TRW5ITVJ?
U-118-MG NVy1XnV4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRThwNEO0OlMh|ryP NVHUZph[W0GQR1XS
SK-OV-3 Mle3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MofBTWM2OD16LkS2O|Y2KM7:TR?= MmnIV2FPT0WU
KNS-62 M2nrWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH\yXHVKSzVyPUiuOVE4PjFizszN MXrTRW5ITVJ?
GOTO MmfNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoX4TWM2OD16LkW3OlM2KM7:TR?= M17MdnNCVkeHUh?=
8305C MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NULhTGdmUUN3ME24MlcxPDh2IN88US=> NILHTGhUSU6JRWK=
RPMI-2650 MnrtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHSwZmNKSzVyPUiuO|E6PTVizszN Mkf6V2FPT0WU
NEC8 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIDST5NKSzVyPUiuO|Q{ODdizszN NXTmO4EyW0GQR1XS
KYSE-450 NUO4dVFzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkjJTWM2OD16Lki2OVQ5KM7:TR?= MV7TRW5ITVJ?
RMG-I MmPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYfmdlNrUUN3ME25MlE1ODV6IN88US=> M{WxfHNCVkeHUh?=
CAKI-1 NVrEd4dkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2DmU2lEPTB;OT6zNVk4QSEQvF2= MXzTRW5ITVJ?
KYSE-510 NXPGRY5sT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NID2cGRKSzVyPUmuN|U4PzhizszN NULlXVdCW0GQR1XS
A4-Fuk MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;0cpZnUUN3ME25MlM3PzBzIN88US=> MWDTRW5ITVJ?
AN3-CA M2POfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV3GO2s2UUN3ME25MlQ2PDR2IN88US=> MXzTRW5ITVJ?
SK-N-DZ M4DkTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWHmPW9LUUN3ME25MlczQDR7IN88US=> MVjTRW5ITVJ?
HSC-2 NHvyTYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTlwN{[2Nlkh|ryP MmXGV2FPT0WU
EW-1 NH7pZ3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTlwN{mzOlkh|ryP MVzTRW5ITVJ?
D-566MG NF\lW4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWGye4Q2UUN3ME25Mlg{PjZ2IN88US=> NILjcI5USU6JRWK=
COLO-792 M3KzTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnBUHRpUUN3ME25Mlk5PzR4IN88US=> NVz1ToV2W0GQR1XS
TE-10 NXfNd2djT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjKc4dbUUN3ME2xNE4xOzl4IN88US=> MmfmV2FPT0WU
NCI-H650 M{nvWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2TrWWlEPTB;MUCuOFI5PiEQvF2= NHHnbJlUSU6JRWK=
U-266 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHHHcXFKSzVyPUGwMlQ2PSEQvF2= M13KdnNCVkeHUh?=
Detroit562 NELXdFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|UxRTFzLkC1NVUh|ryP NHf6UpZUSU6JRWK=
NH-12 M17yT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIK1[YVKSzVyPUGxMlE1PDZizszN NIDhd|VUSU6JRWK=
CO-314 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlLMTWM2OD1zMT6yPFQzKM7:TR?= NHW4dXdUSU6JRWK=
IST-MEL1 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXnkPJFOUUN3ME2xNU42OzJ|IN88US=> NEf5U3lUSU6JRWK=
KNS-81-FD NFPmNZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTFzLkW1Nlch|ryP NW\iPZNEW0GQR1XS
SW1463 M{G5dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\MeGlEPTB;MUGuOVk5QSEQvF2= Mo\6V2FPT0WU
NCI-H23 NUT1SZVNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXm2UlFUUUN3ME2xNU43PTV{IN88US=> M1\rbXNCVkeHUh?=
SK-MEL-2 M3LhUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTFzLkexPVch|ryP NYK3O4tLW0GQR1XS
NB13 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTWOFh7UUN3ME2xNk4yPDl3IN88US=> NFvRXYlUSU6JRWK=
Daoy NYXyfVZyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;TXXdKSzVyPUGyMlI5PTZizszN NXfVVHN6W0GQR1XS
NCI-H1623 Mk\WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGXwSJBKSzVyPUGyMlM5ODFizszN MVHTRW5ITVJ?
NMC-G1 NIfGWI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHfJOnlKSzVyPUGyMlcyPyEQvF2= M{PuSHNCVkeHUh?=
DK-MG NGDC[ZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXLRbJV1UUN3ME2xNk46PDh{IN88US=> MX\TRW5ITVJ?
TCCSUP MoPpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{XvcGlEPTB;MUOuNVI5PCEQvF2= NIThO4NUSU6JRWK=
SCC-15 MnPpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVHXO3dCUUN3ME2xN{4zPjVzIN88US=> NHf6dmVUSU6JRWK=
NOS-1 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTF|LkK4PVMh|ryP M4H3VXNCVkeHUh?=
RH-1 NXP1UHhuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoP1TWM2OD1zMz6zNFM4KM7:TR?= MkLVV2FPT0WU
SK-MEL-3 NEnnRW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3ezUGlEPTB;MUOuN|czQCEQvF2= MVPTRW5ITVJ?
NB5 NVvYfYRIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17mVWlEPTB;MUOuOFA3PyEQvF2= MULTRW5ITVJ?
SNU-387 NVvGV214T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTF|LkWwO|Ih|ryP NYDNfpk2W0GQR1XS
CAL-120 NGLOcHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;4foRKSzVyPUGzMlY4OThizszN NWDwTGNIW0GQR1XS
Mo-T M1LEPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRTF|LkewO{DPxE1? NID3UmdUSU6JRWK=
LNCaP-Clone-FGC MlrMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVnJR|UxRTF|Lke5PVIh|ryP M2O0OXNCVkeHUh?=
CAN NU\MSHg1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\LdW9KSzVyPUG0MlAzQDhizszN M1jwUXNCVkeHUh?=
SK-MEL-30 NWTHOIdQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2LZbWlEPTB;MUSuNFY{KM7:TR?= NHnpdodUSU6JRWK=
COLO-678 NXHkZoxCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrvcWRKSzVyPUG0MlA5OjJizszN NI[yXpBUSU6JRWK=
SCC-9 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn[zTWM2OD1zND6xNFIyKM7:TR?= MVrTRW5ITVJ?
KINGS-1 MorKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPPOpFKSzVyPUG0MlE1ODJizszN MXHTRW5ITVJ?
SL-513 MmnZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnGyTWM2OD1zND6xPFch|ryP NXfx[mZUW0GQR1XS
HLE M2XaOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mmj1TWM2OD1zND6zPFUzKM7:TR?= NXKzd3NpW0GQR1XS
SW1573 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTF2LkS0N|Uh|ryP NX;qPJNPW0GQR1XS
KYSE-140 NUDWeG5FT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHKcFRKSzVyPUG0MlY{OjdizszN NEjEW2hUSU6JRWK=
SK-PN-DW NVS4Rm9{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTF2LkiwNFEh|ryP MUTTRW5ITVJ?
A253 MonyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2HRd2lEPTB;MUWuNFYzPSEQvF2= MV3TRW5ITVJ?
CAL-12T NIHSc3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2DOc2lEPTB;MUWuOFY3OiEQvF2= NEfoOZhUSU6JRWK=
COLO-679 NIToTGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWrIUHRrUUN3ME2xOU44Pjh|IN88US=> M37FTHNCVkeHUh?=
UACC-257 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUXTRlZpUUN3ME2xOk4yOjBzIN88US=> Mm\OV2FPT0WU
U-87-MG Mn7QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{C2OmlEPTB;MU[uN|UzOyEQvF2= MV7TRW5ITVJ?
HCC1806 MnnSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTF4LkewO|Eh|ryP NUflRZFKW0GQR1XS
NCI-H2170 NUjX[JRjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{e0OGlEPTB;MUeuNlQ1QCEQvF2= MljyV2FPT0WU
AGS NETLUmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4jITmlEPTB;MUeuN|gxQCEQvF2= M1zG[nNCVkeHUh?=
MEL-HO M2P6emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTF5Lke1NFMh|ryP MmnGV2FPT0WU
SW48 M4XjU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3OzU2lEPTB;MUeuO|cyPiEQvF2= M1LIVHNCVkeHUh?=
HuP-T4 Mnj0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWOycXpFUUN3ME2xPE4xOjB4IN88US=> NH\OeWVUSU6JRWK=
NCI-H720 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHzjVZJKSzVyPUG4MlE1ODJizszN MVLTRW5ITVJ?
RCC10RGB M4PZVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;0OmlEPTB;MUiuNVY6PyEQvF2= NF7oe4hUSU6JRWK=
HD-MY-Z Mk\nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVXneGZ1UUN3ME2xPE4zOjV2IN88US=> MV3TRW5ITVJ?
A427 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTF6LkWwPVQh|ryP MmPwV2FPT0WU
HCC2998 NXPSVXMyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTF6Lk[wOVEh|ryP NHG3[nlUSU6JRWK=
EPLC-272H M2LJWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLmbXJbUUN3ME2xPU4xPDN2IN88US=> NHzYOW1USU6JRWK=
C32 M2rVXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTF7LkC0OUDPxE1? M2\lOHNCVkeHUh?=
UMC-11 NV3LXINHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M12xZWlEPTB;MUmuNlEzOyEQvF2= MYjTRW5ITVJ?
CaR-1 NGfvTGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{HWdGlEPTB;MUmuOlgxPCEQvF2= NEPyXphUSU6JRWK=
KYSE-410 MnWwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTF7LkmxN|kh|ryP M362RnNCVkeHUh?=
HuCCT1 NITvVmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1faZmlEPTB;MkCuOlI6PCEQvF2= NHHPXWlUSU6JRWK=
LB996-RCC NIPBN5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTJyLkexOlgh|ryP M2POUHNCVkeHUh?=
KYSE-70 NXjLOGVHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFjUOYJKSzVyPUKwMlgxPTlizszN MWDTRW5ITVJ?
CAL-72 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTJyLkmxOUDPxE1? MkP5V2FPT0WU
Capan-2 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnzBTWM2OD1{MT6wOFE{KM7:TR?= MV7TRW5ITVJ?
PANC-08-13 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGPvXm1KSzVyPUKxMlI2OTVizszN MUfTRW5ITVJ?
SBC-1 NFGxe4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\wTWM2OD1{MT6zNFgyKM7:TR?= MmnNV2FPT0WU
MFM-223 NYD0OY5GT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEXHelNKSzVyPUKxMlM{PDJizszN M173cXNCVkeHUh?=
BB49-HNC MoLrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjyd4NKSzVyPUKxMlU4OTZizszN NV3nOmhyW0GQR1XS
SH-4 M3;VT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWnYTGR4UUN3ME2yNU43PjF6IN88US=> NHOyVIJUSU6JRWK=
HuO9 NWrKdFU3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXfEWlhbUUN3ME2yNU46QDJ3IN88US=> NV31[IJmW0GQR1XS
AM-38 NEm4NVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\NO4JKSzVyPUKyMlA1QDVizszN NGLsO5pUSU6JRWK=
A431 M2PTfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fXSGlEPTB;MkOuNlEyQSEQvF2= Mn32V2FPT0WU
YAPC MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVL5PIZZUUN3ME2yN{4zPjVzIN88US=> NF21b|RUSU6JRWK=
LU-139 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnjrTWM2OD1{Mz60PFA6KM7:TR?= M336R3NCVkeHUh?=
HEC-1 NXLGeXU5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2\mOmlEPTB;MkOuOFk{PyEQvF2= MnW4V2FPT0WU
SCC-25 M2n3Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnTVTWM2OD1{ND6zNFA3KM7:TR?= MVXTRW5ITVJ?
HT-29 NYTHUZR3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTJ2LkO4NlMh|ryP M2rXfXNCVkeHUh?=
PC-14 NIPEfI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVy5NpJmUUN3ME2yOE43PTdzIN88US=> NVK5SHFjW0GQR1XS
Calu-6 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\BcmlEPTB;MkWuOVA4OSEQvF2= NF3Vc|ZUSU6JRWK=
SJRH30 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml23TWM2OD1{NT62OFk3KM7:TR?= MlHwV2FPT0WU
ChaGo-K-1 M2[1Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTJ4LkG2Nlkh|ryP NFnVbW9USU6JRWK=
IA-LM M2DNbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTJ4LkO2OFUh|ryP MXrTRW5ITVJ?
GP5d NWiwR2RVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnqxTWM2OD1{Nj60OFkyKM7:TR?= M{DHUHNCVkeHUh?=
NCI-H2291 MlLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLXTWM2OD1{Nj62OVQyKM7:TR?= M3rpPXNCVkeHUh?=
BALL-1 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTJ4LkmzPVch|ryP MXTTRW5ITVJ?
HCC1954 NHKwfW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIfYcphKSzVyPUK2Mlk5ODhizszN MVfTRW5ITVJ?
NCI-H2452 Mmj0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH7aSFdKSzVyPUK3MlQyPjNizszN MXjTRW5ITVJ?
LU-99A MonpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF[xe|dKSzVyPUK3MlU2QDJizszN NIPZcnVUSU6JRWK=
NTERA-S-cl-D1 NHn5e2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLTTWM2OD1{Nz63Nlk6KM7:TR?= M4HtTnNCVkeHUh?=
PANC-10-05 MoXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYLWRYVGUUN3ME2yO{44Pzd3IN88US=> NYjjdmRQW0GQR1XS
NCI-H2405 NGnieo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTJ5LkmzPFch|ryP MVvTRW5ITVJ?
MDA-MB-415 MmfKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTJ6LkSxN|ch|ryP M3XaO3NCVkeHUh?=
NCI-H2342 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTJ6LkWyPFEh|ryP NVXETJdJW0GQR1XS
TGBC24TKB MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX7JR|UxRTJ6LkexNVch|ryP NUm3b3N6W0GQR1XS
LU-134-A M2\Udmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXnvbVNHUUN3ME2yPE46OjZzIN88US=> M3HpWXNCVkeHUh?=
SCC-4 M4\ob2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTNzLkC0PVQh|ryP NYPRZ5VbW0GQR1XS
Saos-2 NVfOWI8zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFT6d2dKSzVyPUOxMlk{ODZizszN NWTOOZJsW0GQR1XS
RERF-LC-MS NF7w[VhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\3PJlKSzVyPUOyMlgzOzFizszN NIDGUYhUSU6JRWK=
M14 Ml7CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRTN{Lkm3OlQh|ryP MnO0V2FPT0WU
HPAF-II NEDM[JRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\hdVBKSzVyPUOzMlUxOTFizszN MmnYV2FPT0WU
NCI-H1755 MkHSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkDXTWM2OD1|ND6zN|A2KM7:TR?= MkDIV2FPT0WU
D-392MG MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\rOmhuUUN3ME2zOU45Pjd2IN88US=> Mn:0V2FPT0WU
A704 MlniS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTN4LkC0Nlch|ryP NVWxZ|JbW0GQR1XS
CP50-MEL-B NV[xRlZ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\XTWM2OD1|Nj6xPVEyKM7:TR?= MWnTRW5ITVJ?
EW-18 NV7xWplpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUT0NWpZUUN3ME2zOk41PTJizszN M2nYdXNCVkeHUh?=
WM-115 MojYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEj0fHFKSzVyPUO2MlgxQTlizszN MWXTRW5ITVJ?
LU-65 MmjvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXrhUpB{UUN3ME2zO{4yPDF5IN88US=> MlX0V2FPT0WU
NCI-H1563 M3GzVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3r1OGlEPTB;M{euNlQ5PCEQvF2= M2jvNXNCVkeHUh?=
DBTRG-05MG NGXoZpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXTxepZFUUN3ME2zPE4xPjlzIN88US=> MYLTRW5ITVJ?
NCI-H630 NVjvdYpIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml7uTWM2OD1|OD60O|E1KM7:TR?= NUP4bldKW0GQR1XS
NCI-H1155 NU\5cVlbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWnoPFdtUUN3ME2zPU4zPDJizszN MYfTRW5ITVJ?
OVACR-3 NET4bWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmG3TWM2OD1|OT65NVk2KM7:TR?= NVTYS3l6W0GQR1XS
OAW-42 NX;xTHdYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEH1fHJKSzVyPUSwMlQzPThizszN NVTVfGw2W0GQR1XS
JVM-2 Mn2yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NET4OFFKSzVyPUSxMlI1OTVizszN Mm\UV2FPT0WU
C3A M3fEXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M361cmlEPTB;NEGuN|Q1PyEQvF2= M1vOe3NCVkeHUh?=
HT55 Ml3jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFGxS4NKSzVyPUSyMlI5PDFizszN Ml7EV2FPT0WU
OVCAR-4 Mk\DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRTR{LkK5O|Qh|ryP NULGPJkzW0GQR1XS
MEG-01 NEnyeIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1;DeWlEPTB;NEKuOFYyPiEQvF2= NVv6V|V2W0GQR1XS
NCI-H82 NGK3fIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWi0PIloUUN3ME20N{46QDl{IN88US=> MkfBV2FPT0WU
JEG-3 NU\mWoplT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTR2Lkm0O{DPxE1? NETaTWlUSU6JRWK=
BPH-1 NVf1e2ZQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnT4TWM2OD12Nj6zPVk5KM7:TR?= MWLTRW5ITVJ?
MPP-89 M1z0VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn:0TWM2OD12Nz6yPFk5KM7:TR?= MYXTRW5ITVJ?
ALL-PO NEL2Wo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTR5LkSxPFgh|ryP Mn\tV2FPT0WU
HT NIHYWZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX7ub|BbUUN3ME20O{41QTJizszN NYOxPHAxW0GQR1XS
NCI-H2347 NXnTZVF4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1zEOGlEPTB;NEiuNFcyPSEQvF2= NHXQWI1USU6JRWK=
A2780 NWjv[VFKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4D1NmlEPTB;NEmuOFIzQCEQvF2= MlWzV2FPT0WU
KARPAS-299 MkGxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M37zPGlEPTB;NEmuOVEyQSEQvF2= NF2xcJZUSU6JRWK=
NCI-H1651 MoixS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{TKZmlEPTB;NEmuPFgzOSEQvF2= NV:xbGtvW0GQR1XS

... Click to View More Cell Line Experimental Data

In vivo PD 0332991 indicates complete tumor stasis in a MDA-MB-435 xenograft at 150 mg/kg. PD 0332991 also shows broad-spectrum antitumor activity in multiple human tumor xenografts by eliminating phospho-Rb and the proliferative marker Ki-67 from tumor tissue and down-regulation of genes under the transcriptional control of E2F. [1]

Protocol

Kinase Assay:

[1]

+ Expand

Cdk Assays:

A stock solution of PD0332991 is prepared in DMSO. CDK assays are performed in 96-well filter plates. All CDK-cyclin kinase complexes are expressed in insect cells through baculovirus infection and purified. The substrate for the assays is a fragment (amino acids 792–928) of pRb fused to GST (GST·RB-Cterm). The total volume in each well is 0.1 mL containing a final concentration of 20 mM Tris-HCl, pH 7.4, 50 mM NaCl, 1 mM dithiothreitol, 10 mM MgCl2, 25 μM ATP (for CDK4-cyclin D1, CDK6-cyclin D2, and CDK6-cyclin D3) or 12 μM ATP (for CDK2-cyclin E, CDK2-cyclin A, and CDC2-cyclin B) containing 0.25 μCi of [γ-32P]ATP, 20 ng of enzyme, 1 μg of GST·RB-Cterm, and PD 0332991 (0.001-0.1μM). All components except the [γ-32P]ATP are added to the wells, and the plate is placed on a plate mixer for 2 min. The reaction is started by adding the [γ-32P]ATP and the plate is incubated at 25 °C for 15 min. The reaction is terminated by addition of 0.1 mL of 20% trichloroacetic acid and the plate is kept at 4  °C for at least 1 hour to allow the substrate to precipitate. The wells are then washed 5 times with 0.2 mL of 10% trichloroacetic acid and radioactive incorporation is determined with a β plate counter.
Cell Research:

[1]

+ Expand
  • Cell lines: Tumor cell lines including MDA-MB-435, ZR-75-1, T-47D, MCF-7, H1299, Colo-205, MDA-MB-468, H2009, CRRF-CEM and K562
  • Concentrations: 0.01-1 μM
  • Incubation Time: 24 hours
  • Method:

    Cells are seeded at 2 × 104 per well in a 96-well plate and incubated overnight. PD 0332991 (0.01-1 μM) is added to the wells and incubated at 37 °C for another 24 hours. [14C]Thymidine (0.1 μCi) is added to each well and incorporation of the radiolabel is allowed to proceed for 72 hours. Incorporated radioactivity is determined with a β plate counter.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: Advanced stage human tumor xenografts including Colo-205, MDA-MB-435 breast, SF-295 glioblastoma, ZR-75-1 breast, PC-3 prostate, H125 lung, SW-620 colon, H23 lung and MDA-MB-468 breast (Rb negative) are established in severe combined immunodeficient mice.
  • Formulation: Dissolved in sodium lactate buffer (50 mM, pH 4.0)
  • Dosages: 0-150 mg/kg
  • Administration: Given by gavage
    (Only for Reference)

Solubility (25°C)

In vitro Water 30 mg/mL (61.98 mM)
DMSO 3 mg/mL warmed (6.19 mM)
Ethanol Insoluble
In vivo Add solvents to the product individually and in order:
Saline
For best results, use promptly after mixing.
20 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 483.99
Formula

C24H29N7O2.HCl

CAS No. 827022-32-2
Storage powder
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03007979 Not yet recruiting Breast Cancer|Breast Carcinoma|Cancer of Breast|Malignant Tumor of Breast Washington University School of Medicine February 28, 2017 Phase 2
NCT02907918 Not yet recruiting Breast Cancer|Cancer of Breast|Breast Carcinoma Washington University School of Medicine|Pfizer February 28, 2017 Phase 2
NCT01209598 Completed Sarcoma|Liposarcoma Memorial Sloan Kettering Cancer Center|Pfizer September 23, 2010 Phase 2
NCT03054363 Not yet recruiting Breast Cancer University of Colorado, Denver March 2017 Phase 1|Phase 2
NCT03024489 Not yet recruiting Head and Neck Cancer|Locally Advanced|Unresectable Mahidol University February 2017 Phase 1|Phase 2
NCT02947685 Not yet recruiting HER-2 Positive Breast Cancer|Estrogen Receptor Positive Breast Cancer Alliance Foundation Trials, LLC.|Pfizer|German Breast Group (GBG)|Fondazione Michelangelo|PrECOG, LLC.|The Australia and New Zealand Breast Cancer Trials Group (ANZBCTG)|Alliance Foundation Trials Biorepository - Washington State University|Alliance Foundation Trials Central Imaging Core Lab - Ohio State University|Mastering Breast Cancer Initiative, LLC|Mayo Clinic Statistics and Data Center|INC Research|SOLTI Breast Cancer Research Group February 2017 Phase 3

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    There are two kind of Palbociclibs available: the isethionate salt or the HCl salt. I would like to know which is the main difference between them and what are they more suitable for in terms of experiment type (cell culture or in vivo animals experiments).

  • Answer:

    This two compounds are different Palbociclib salt. S1579 is the Isethionate salt, and the S1116 is the HCl salt. you can use S1116 for oral administration while S1579 is more suitable for I.P. administration.

CDK Signaling Pathway Map

CDK Inhibitors with Unique Features

Related CDK Products

Tags: buy Palbociclib (PD-0332991) HCl | Palbociclib (PD-0332991) HCl supplier | purchase Palbociclib (PD-0332991) HCl | Palbociclib (PD-0332991) HCl cost | Palbociclib (PD-0332991) HCl manufacturer | order Palbociclib (PD-0332991) HCl | Palbociclib (PD-0332991) HCl distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID